UK markets close in 12 minutes

BIIB Jan 2026 310.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
12.000.00 (0.00%)
As of 03:17PM EDT. Market open.
Full screen
Previous close12.00
Open12.00
Bid15.00
Ask24.90
Strike310.00
Expiry date2026-01-16
Day's range12.00 - 12.00
Contract rangeN/A
Volume2
Open interest83
  • Reuters

    REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug

    Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study. Shares of Biogen and Ionis were each down nearly 2% in premarket trading. This marks another setback in the search for new treatments for ALS, a rare neurodegenerative disease that affects the voluntary control of limbs and leads to breathing trouble.

  • GlobeNewswire

    Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

    Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CAMBRIDGE, Mass. and CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) anno

  • PR Newswire

    Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

    Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on topline results from the Phase 1/2 ALSpire study. BIIB105 was designed to reduce expression of ataxin-2 (ATXN2) protein and demonstrated statistically significant cerebrospinal fluid (CSF) ATXN2 protein reductions in the study. However, over the 6-month plac